DHRS9 Inhibitors
DHRS9 Inhibitors affect the function of DHRS9 by interfering with the signaling pathways it interacts with or by influencing its enzymatic activity. Retinoic acid and Isotretinoin are metabolites that DHRS9 acts upon, and increasing their concentration can saturate DHRS9, leading to a relative decrease in its functional activity.
Several DHRS9 inhibitors are kinase inhibitors that target pathways DHRS9 is involved in. For example, LY294002 and Wortmannin both inhibit PI3K, leading to a decrease in DHRS9's activities linked with PI3K signaling. Staurosporine, a potent inhibitor of PKC, can decrease the functional activities of DHRS9, which is known to interact with proteins involved in PKC signaling pathways. Similarly, PD98059 and U0126 inhibit MEK, which is upstream of ERK in the MAPK pathway. DHRS9 interacts with proteins in the MAPK pathway, so blocking MEK and thus reducing ERK activation can indirectly lead to the inhibition of DHRS9. SB203580, a p38 MAPK inhibitor, leads to a decrease in DHRS9's activity by affecting the MAPK signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, a key kinase in several signaling pathways. DHRS9 is involved in the regulation of innate immune responses that are linked with PI3K signaling. The inhibition of PI3K by LY294002 can lead to a decrease in the functional activities of DHRS9. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. As DHRS9 interacts with proteins that are downstream targets of PI3K, inhibiting PI3K by Wortmannin can lead to a decrease in DHRS9's functional activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, including PKC. DHRS9 is known to interact with proteins involved in PKC signaling pathways. Therefore, the inhibition of PKC by Staurosporine can lead to a decrease in the functional activities of DHRS9. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which is upstream of ERK in the MAPK pathway. Given that DHRS9 interacts with proteins in the MAPK pathway, blocking MEK and thus reducing ERK activation can indirectly lead to the inhibition of DHRS9. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Since DHRS9 can interact with proteins involved in MAPK signaling, SB203580 can inhibit p38 MAPK, leading to a decrease in DHRS9's functional activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK, which is involved in actin cytoskeleton reorganization. Given that DHRS9 is associated with proteins that regulate actin remodeling, inhibiting ROCK can indirectly reduce DHRS9's functional activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family kinases, which interact with proteins containing SH3 domains. Since DHRS9 can interact with proteins that involve SH3 domains, PP2 can indirectly inhibit DHRS9's function by blocking the activation of proteins with SH3 domains. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, a kinase involved in various signaling pathways. As DHRS9 interacts with proteins that are downstream targets of JNK, inhibiting JNK can indirectly lead to a decrease in DHRS9's functional activity. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. As DHRS9 can interact with proteins phosphorylated by tyrosine kinases, Genistein can inhibit these kinases, leading to a decrease in DHRS9's functional activity. | ||||||